Africa Centres for Disease Control and Prevention (2023) Guidelines for Enhanced Surveillance of Sudan Virus Disease. Africa Centres for Disease Control and Prevention.

Ahmad, B. et al. (2019) ‘Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach’, Microbial Pathogenesis, 132, pp. 243–253. Available at: https://doi.org/10.1016/j.micpath.2019.05.010.

Babirye, P. et al. (2018) ‘Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease’, BMC Infectious Diseases, 18(1), p. 498. Available at: https://doi.org/10.1186/s12879-018-3409-x.

Brannan, J.M. et al. (2019) ‘Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates’, Nature Communications, 10, p. 105. Available at: https://doi.org/10.1038/s41467-018-08040-w.

Dias, J.M. et al. (2011) ‘A shared structural solution for neutralizing ebolaviruses’, Nature Structural & Molecular Biology, 18(12), pp. 1424–1427. Available at: https://doi.org/10.1038/nsmb.2150.

Evans, J.S. et al. (2018) ‘Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses’, Journal of General Virology, 99(2), pp. 169–180. Available at: https://doi.org/10.1099/jgv.0.000998.

Ferrara, F. and Temperton, N. (2018) ‘Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis’, Methods and Protocols, 1(1), p. 8. Available at: https://doi.org/10.3390/mps1010008.

Flyak, A.I. et al. (2018) ‘Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region’, Nature Microbiology, 3(6), pp. 670–677. Available at: https://doi.org/10.1038/s41564-018-0157-z.

Gilchuk, P. et al. (2018) ‘Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein’, Immunity, 49(2), pp. 363-374.e10. Available at: https://doi.org/10.1016/j.immuni.2018.06.018.

Hargreaves, A. et al. (2021) ‘Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application’, Pathogens, 10(9), p. 1201. Available at: https://doi.org/10.3390/pathogens10091201.

Heckman, K.L. and Pease, L.R. (2007) ‘Gene splicing and mutagenesis by PCR-driven overlap extension’, Nature Protocols, 2(4), pp. 924–932. Available at: https://doi.org/10.1038/nprot.2007.132.

Howell, K.A. et al. (2016) ‘Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site’, Cell Reports, 15(7), pp. 1514–1526. Available at: https://doi.org/10.1016/j.celrep.2016.04.026.

Jespersen, M.C. et al. (2017) ‘BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes’, Nucleic Acids Research, 45(W1), pp. W24–W29. Available at: https://doi.org/10.1093/nar/gkx346.

Jumper, J. et al. (2021) ‘Highly accurate protein structure prediction with AlphaFold’, Nature, 596(7873), pp. 583–589. Available at: https://doi.org/10.1038/s41586-021-03819-2.

Lennemann, N.J. et al. (2021) ‘A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner’, Journal of Virology. Edited by R.E. Dutch, 95(18), pp. e01073-21. Available at: https://doi.org/10.1128/JVI.01073-21.

Misasi, J. and Sullivan, N.J. (2021) ‘Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein’, Immunity, 54(3), pp. 412–436. Available at: https://doi.org/10.1016/j.immuni.2021.01.015.

Rutledge, R.D. et al. (2008) ‘Design and synthesis of an antigenic mimic of the Ebola glycoprotein’, Journal of Materials Research, 23(12), pp. 3161–3168. Available at: https://doi.org/10.1557/JMR.2008.0384.

Sanchez-Lockhart, M. et al. (2018) ‘Qualitative Profiling of the Humoral Immune Response Elicited by rVSV-ΔG-EBOV-GP Using a Systems Serology Assay, Domain Programmable Arrays’, Cell Reports, 24(4), pp. 1050-1059.e5. Available at: https://doi.org/10.1016/j.celrep.2018.06.077.